{"id":"NCT00471497","sponsor":"Novartis Pharmaceuticals","briefTitle":"A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)","officialTitle":"A Phase III Multi-center, Open-label, Randomized Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-07-31","primaryCompletion":"2009-09-02","completion":"2019-08-21","firstPosted":"2007-05-10","resultsPosted":"2013-06-17","lastUpdate":"2020-11-18"},"enrollment":846,"design":{"allocation":"RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Myelogenous Leukemia, Chronic"],"interventions":[{"type":"DRUG","name":"nilotinib","otherNames":["AMN107"]},{"type":"DRUG","name":"imatinib","otherNames":["STI571"]}],"arms":[{"label":"nilotinib 300mg bid (investigating arm)","type":"EXPERIMENTAL"},{"label":"Nilotinb 400 mg bid (investigating arm)","type":"EXPERIMENTAL"},{"label":"imatinib 400mg QD (control arm)","type":"EXPERIMENTAL"}],"summary":"In this study, the efficacy and safety of two nilotinib doses, 300 mg twice daily and 400 mg twice daily, were compared with imatinib 400 mg once daily in newly diagnosed patients with Philadelphia chromosome-positive (Ph+) Chronic Myelogenous Leukemia in the chronic phase (CML-CP).\n\nAn extension protocol was included in this study design to allow patients who did not show sufficient response to their assigned treatments the opportunity to receive imatinib 400 mg BID (option available until protocol amendment 7) or nilotinib 400 mg BID, using an abbreviated safety and efficacy assessment schedule.","primaryOutcome":{"measure":"Major Molecular Response Rate (MMR) at 12 Months Between All 3 Arms - With Imputation","timeFrame":"Baseline, 12 months","effectByArm":[{"arm":"Imatinib 400 mg QD","deltaMin":22.3,"sd":null},{"arm":"Nilotinb 300 mg BID","deltaMin":44.3,"sd":null},{"arm":"Nilotinib 400 mg BID","deltaMin":42.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":7},"locations":{"siteCount":213,"countries":["United States","Argentina","Austria","Belgium","Brazil","Canada","Colombia","Czechia","Denmark","Egypt","Finland","France","Germany","Hong Kong","Hungary","Italy","Japan","Malaysia","Mexico","Netherlands","Norway","Poland","Russia","Singapore","Slovakia","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","Turkey (TÃ¼rkiye)","United Kingdom","Venezuela"]},"refs":{"pmids":["24532039","24335106","23502220","23109697","22207416","21856226","21467546","20525993"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":96,"n":280},"commonTop":["Rash","Headache","Nausea","Diarrhoea","Nasopharyngitis"]}}